AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03803566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegboard practice
Description: Practice of the grooved pegboard test
Study NCT03803566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force control practice
Description: Practice performing steady muscle contractions
Study NCT06088771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
Study NCT06088771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
Study NCT05450770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
Study NCT05450770 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
Study NCT05805475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning with expiratory pause
Description: Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
Study NCT05805475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal suctioning without expiratory pause
Description: Perform closed endotracheal suctioning without expiratory pause
Study NCT06251921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration
Description: with resin-based composite
Study NCT05582629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: JT001 administered orally in tablet form every 12 hours for 5 days
Study NCT05582629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
Study NCT05335655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: IV initial bolus and trans operative dexmedetomidine infusion.
Study NCT05335655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% infusion
Description: IV initial bolus and trans operative infusion of 0.9% saline solution.
Study NCT06303206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)
Description: Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Case Management (CM) includes pharmacists reviewing BP data and providing counselling to participants based on their BP values.
Study NCT05116254 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: AZD1390 + radiotherapy
Description: AZD1390 combined with preoperative radiotherapy
Study NCT05116254 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: AZD1390 + durvlaumab + radiotherapy
Description: AZD1390 combined with durvalumab and preoperative radiotherapy
Study NCT05205980 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Perturbation training
Description: Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
Study NCT05205980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation training
Description: Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
Study NCT06544746 — intervention group
Intervention type: RADIATION
Intervention: Periapical radiographs
Description: oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.
Study NCT05358990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Language Recommendation (PLR)
Description: New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
Study NCT05358990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Language Version (SLV)
Description: Original recommendation as initially published by the guideline organization.
Study NCT06248684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standardized prevention and therapy measures
Description: Patients from the age of 65 years with an additional risk factor for postoperative delirium are assigned to a multidimensional standardized perioperative care protocol.
Study NCT04666610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.
Study NCT04666610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding.
Study NCT05473299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeltis Hemodialysis Access (aXess) graft
Description: The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
Study NCT05645757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
Study NCT05645757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05645757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 6777
Description: A combination of ertapenem (ERT) and zidebactam (ZID)
Study NCT05645757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidebactam
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
Study NCT06087588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%sodium chloride
Description: PENG sham block with 20ml 0,9% normal saline
Study NCT06087588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 95% ethanol
Description: PENG neurolysis with 2.5ml of 95% ethanol
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone Acetate
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darolutamide
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT06120491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Oral
Study NCT06559618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phage Therapy
Description: A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
Study NCT06559618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
Study NCT05594238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Engagement
Description: Brief phone session with a study counselor.
Study NCT05594238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Engagement
Description: Access to a virtual portal where participant messages with study counselors.
Study NCT05594238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI-CBT
Description: 8 one-on-one sessions done over the phone or video chat with a study counselor
Study NCT06225596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
Study NCT06225596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
Study NCT06225596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
Study NCT06225596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
Study NCT06225596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin Or carboplatin
Description: Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
Study NCT06225596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
Study NCT05175105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets or granules
Study NCT05175105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat-matching placebo
Description: Tablets or granules
Study NCT05175105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat-matching placebo
Description: Tablets or granules
Study NCT04471246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: 1000 mg PO QID for 7 days
Study NCT04471246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin + placebo
Description: 500 mg PO QID plus oral placebo for 7 days
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT05624996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT05624996 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT
Study NCT05624996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT05624996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05624996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05624996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05624996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05624996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05624996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05624996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06438302 — intervention group
Intervention type: DEVICE
Intervention: EEG activity measurement
Description: The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 31°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition.
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Administered intravenously (IV)
Study NCT06282575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered intravenously (IV)
Study NCT06112418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Cleerly CAD Staging System
Description: The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
Study NCT06402006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: pericapsular nerve group block
Study NCT06402006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LFCN block
Description: Lateral femoral cutaneous nerve block
Study NCT06402006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: Erector spinae plane block
Study NCT04833010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test
Description: Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
Study NCT04833010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test
Description: Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
Study NCT04833010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Performance Test
Description: Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
Study NCT04833010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Performance Test
Description: Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
Study NCT04672655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONBOARD
Description: Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
Study NCT06566443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honokiol
Description: Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
Study NCT06387472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI algorithm to evaluate photographs of skin test patch regions
Description: Interpretation of skin test patch regions via artificial intelligence (AI)
Study NCT06387472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergen Patch
Description: Contains dime-sized disks which have different substance to which a person may be allergic.
Study NCT05342701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Skills Intervention
Description: The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity.
Study NCT05232838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eShunt Implant
Description: The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
Study NCT05104515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVM-200
Description: The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer.
Study NCT06525532 — intervention group
Intervention type: OTHER
Intervention: follow up
Description: performing a 3 Tesla MRI of the operated foot
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples